Publication | Closed Access

EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial

Placebo-controlled Phase 2Pain SyndromeHealth SciencesPain MedicineNovel TreatmentClinical TrialsNeuropathic PainReceptor AntagonistNeuropharmacologyPharmacotherapyNeurologyMedicinePain Research